Key points are not available for this paper at this time.
Delayed diagnosis remains a major obstacle to initiating effective therapy prior to the development of end-stage organ failure. Trials of antibodies to deplete deposited fibrils are underway.
Morie A. Gertz (Thu,) studied this question.